Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SARS-CoV-2 neutralising monoVHH antibody - Immunofusion

Drug Profile

SARS-CoV-2 neutralising monoVHH antibody - Immunofusion

Alternative Names: SARS-CoV-2 omicron monoVHH neutralising antibody -Immunofusion

Latest Information Update: 09 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunofusion
  • Class Antivirals; Immunoglobulin Fc fragments; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 09 Jan 2023 SARS-CoV-2 neutralising monoVHH antibody - Immunofusion is available for licensing as of 09 Jan 2023. https://immunofusion.com/#NEUTRALIZATION_ANTIBODY (Immunofusion pipeline, December 2022)
  • 30 Dec 2022 Antiviral data from early research in COVID-2019 infections released by Immunofusion (Immunofusion pipeline, December 2022)
  • 26 Dec 2022 Immunofusion files for patent for humanized VHH antibody library based receptor binding domain (RBD) binders prior to December 2022 (Immunofusion pipeline, December 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top